


Italy

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous	s survey: ▲ Improvement ▼ Decline	2009		2012		2015		2018
International units	Factor VIII	0.00	A	9.14	•	8.34	A	8.67
per capita	Factor IX	0.00	A	1.20	•	1.12	•	1.04
Organisation	Comprehensive Care Centres (CCC's)	Yes		Yes		Yes		Yes
of care	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
	National Haemophilia Council or Co-ordinating Group	No	_	Yes	•	No		No
	Number of groups in decision-making on haemophilia care	0	_	3	•	2	A	3
	Number of groups choosing haemophilia treatment products	0	A	3	•	2	A	3
	National Tender for procurement of factor concentrates	No		No		No		No
Treatment	Home Treatment	Yes		Yes		Yes		Yes
regimens	% of people with haemophilia using home treatment	76-100%		76-100%		76-100%		76-100%
	Treatment delivered to the patient's home	Some		Some		Some		Some
	Prophylaxis treatment availability	Yes		Yes		Yes		Yes
	Children currently on prophy (%)	51-75%		51-75%	A	76-100%		76-100%
	Adults currently on prophy (%)	26-50%		26-50%	A	51-75%	A	76-100%
	Access to ITI (% of people with inhibitors)	76-99%		76-99%	A	100%	•	76-99%
Access to	Emergency medicine and acute surgery			Yes	•	Sometimes		Sometimes
specialist services	Paediatrics			Yes	•	Sometimes		Sometimes
	Infectious disease specialists (especially HIV)			Yes	•	Sometimes		Sometimes
	Hepatology			Yes	•	Sometimes		Sometimes
	Rheumatology			Sometimes	▼	Never	A	Sometimes
	Orthopaedics			Yes	•	Sometimes		Sometimes
	Physiotherapy			Yes	•	Sometimes		Sometimes
	Dentistry			Yes	•	Sometimes		Sometimes
	Obstetrics and Gynaecology			Yes	•	Sometimes		Sometimes
	Genetics			Yes		Yes	•	Sometimes
	Social and psychological support			Sometimes		Sometimes		Sometimes
	Pain management			Sometimes	▼	Never	A	Sometimes
	General surgery			Yes	•	Never	A	Sometimes
	Urology			Yes	•	Never	A	Sometimes
Share of Expected	Haemophilia A			63%	_	66%	A	68%
Bleeding Disorder	Haemophilia B			42%	A	45%	A	48%
Prevalence	von Willebrand Disease			4%	A	5%	A	5%
Haemophilia	Pasma-derived factor concentrate	Sometimes		Sometimes		Sometimes		Sometimes
replacement	Recombinant factor concentrate	Always		Always		Always		Always
therapy	Plasma	Never		Never		Never		Never
	Cryoprecipitate	Never		Never		Never		Never
VWD replacement	Plasma-derived factor concentrate			Always		Always	•	Rarely
therapy	DDAVP			Always		Always		Always
, ,	Plasma			Never		Never	•	Rarely
	Cryoprecipitate			Never				Rarely